Edition:
United States

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

0.61USD
20 Apr 2018
Change (% chg)

$-0.01 (-1.47%)
Prev Close
$0.62
Open
$0.61
Day's High
$0.63
Day's Low
$0.60
Volume
14,258
Avg. Vol
92,483
52-wk High
$4.59
52-wk Low
$0.51

Select another date:

Wed, Apr 18 2018

BRIEF-Fibrocell Announces Review Of Strategic Alternatives

* FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS

BRIEF-Fibrocell Reports 2017 Financial Results And Recent Highlights

* FIBROCELL REPORTS 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013

* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

BRIEF-Fibrocell Science Says‍ Expect To Initiate A Safety Clinical Trial In 2018 For Fcx-013 Development

* FIBROCELL SCIENCE SAYS‍ EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder

* FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

BRIEF-Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018

* FIBROCELL SCIENCE INC SAYS EXPECTS IND FILING OF FCX-013 IN Q1 2018 AND INITIATE SAFETY CLINICAL TRIAL IN 2018 - SEC FILING Source text: (http://bit.ly/2EaJQ01) Further company coverage:

BRIEF-Fibrocell Science Q3 loss per share $‍0.02​

* Fibrocell reports third quarter 2017 financial results and recent highlights

BRIEF-Fibrocell Science files for common stock offering of up to $23 mln

* Fibrocell Science Inc files for common stock offering of up to $23 million - SEC filing‍​ Source text: (http://bit.ly/2AoC3tG) Further company coverage:

Select another date: